The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic significance of tumor immune microenvironment dynamics in prostate cancer induced by androgen deprivation therapy.
 
Yoshinori Yanai
No Relationships to Disclose
 
Takeo Kosaka
No Relationships to Disclose
 
Shuji Mikami
No Relationships to Disclose
 
Masashi Arai
No Relationships to Disclose
 
Yuto Baba
No Relationships to Disclose
 
Keitaro Watanabe
No Relationships to Disclose
 
Toshikazu Takeda
No Relationships to Disclose
 
Kazuhiro Matsumoto
No Relationships to Disclose
 
Makiko Yamashita
No Relationships to Disclose
 
Shigehisa Kitano
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Janssen; Lilly Japan; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; GlaxoSmithKline; ImmuniT Research Inc.; Ono Pharmaceutical; Rakuten Medical; Sumitomo Dainippon Pharma; United Immunity
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Loxo/Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takara Bio (Inst); Takeda (Inst)
 
Mototsugu Oya
No Relationships to Disclose